AAN 2024 | The HEALEY ALS Platform Trial: a multi-agent evaluation

Jinsy Andrews, MD, FAAN, Columbia University, New York, NY, discusses ongoing investigations in the innovative HEALEY ALS Platform Trial (NCT04297683), which is evaluating therapies for amyotrophic lateral sclerosis (ALS). This trial uses an adaptive platform to test multiple investigational products that may be candidates for confirmatory Phase III trials. Since 2020, five therapies have been evaluated, with two of them showing preliminary activity that warrants further investigation. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.